{"id":12372,"date":"2003-12-01T05:31:29","date_gmt":"2003-12-01T05:31:29","guid":{"rendered":"http:\/\/i-base.info\/htb\/?p=12372"},"modified":"2014-05-27T10:33:45","modified_gmt":"2014-05-27T10:33:45","slug":"us-paediatric-adult-and-maternal-child-guidelines-updated","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/12372","title":{"rendered":"US paediatric, adult and maternal-child guidelines updated"},"content":{"rendered":"<p><strong>US guidelines have been updated, largely to include information on recently approved drugs (T20, atazanavir and FTC) and newly identified interactions (triple-nucleoside, atazanavir etc). The paediatric guidelines also have substantial changes in other sections.<\/strong><\/p>\n<p>The guidelines are now available in pdf file and html format, and very helpfully all new changes are highlighted with yellow background text in the pdf and bold text in the html versions.<\/p>\n<p><a href=\"http:\/\/aidsinfo.nih.gov\/guidelines\/\"> http:\/\/aidsinfo.nih.gov\/guidelines\/<\/a><\/p>\n<p><strong>Guidelines for the use of antiretroviral agents in pediatric HIV infection<\/strong><br \/>\nConvened by the Department of Health and Human Services and the Henry J. Kaiser Family Foundation, 22 September, 2003.<\/p>\n<p><strong>Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents panel on clinical practices for the treatment of HIV<\/strong><br \/>\nConvened by the Department of Health and Human Services and the Henry J. Kaiser Family Foundation, 10 November, 2003.<\/p>\n<p><strong>Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States<\/strong><br \/>\nProduced by Public health service task force on 22 September, 2003, together with a supplement \u2018Safety and toxicity of individual antiretroviral agents in pregnancy\u2019 published on 10 November 2003.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>US guidelines have been updated, largely to include information on recently approved drugs (T20, atazanavir and FTC) and newly identified interactions (triple-nucleoside, atazanavir etc). The paediatric guidelines also have substantial changes in other sections. The guidelines are now available in &hellip;<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[],"class_list":["post-12372","post","type-post","status-publish","format-standard","hentry","category-antiretrovirals"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/12372","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=12372"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/12372\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=12372"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=12372"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=12372"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}